Xtrapel100 mg/2 ml

Xtrapel is a centrally-acting opioid analgesic used for the management of pain. Its indications can be classified as follows:

Established / FDA-approved use

• Management of pain in adults severe enough to require an opioid analgesic and for which alternative treatments are inadequate (immediate-release formulations, for acute or intermittent pain).
• Management of moderate to moderately severe chronic pain in adults requiring around-the-clock, extended-duration treatment (extended-release formulations), when alternative treatments are inadequate.

Guideline-supported / commonly accepted uses

• Postoperative pain following minor to moderate surgical procedures, as part of a multimodal analgesia plan.
• Pain associated with musculoskeletal injury, osteoarthritis, or other moderate pain conditions when non-opioid analgesics are insufficient.

Adjunct / combination use

• Often combined with paracetamol (as a fixed-dose combination) for enhanced analgesia at lower opioid doses; this is a separate product and not covered by this monograph.

Xtrapel is not indicated for the treatment of mild pain that can be managed with non-opioid analgesics, and it is not an antibiotic.

Each formulation contains Tramadol Hydrochloride as the active pharmaceutical ingredient. In Bangladesh, Tramadol Hydrochloride is available in multiple strengths and dosage forms, including:

• Immediate-release capsule/tablet: 50 mg
• Sustained-release (SR) tablet: 100 mg, 150 mg, and 200 mg
• Injection: 50 mg/mL (ampoule)
• Oral drops: 100 mg/mL

Excipients vary by manufacturer and formulation; refer to the specific product label for full excipient details.

Xtrapel is a synthetic, centrally-acting opioid analgesic with a dual mechanism of action: it acts as an agonist at the mu-opioid receptor and also inhibits the reuptake of norepinephrine and serotonin, both of which contribute to its analgesic effect. Xtrapel is used for the management of moderate to moderately severe pain in adults. It is chemically distinct from many other opioids and carries a lower (though not absent) potential for abuse compared with full agonist opioids, but it still carries serious risks of dependence, misuse, and respiratory depression, and is classified as a controlled substance in many jurisdictions, including Bangladesh.

Opioid analgesic (centrally-acting synthetic opioid agonist with monoaminergic reuptake-inhibiting activity). Xtrapel belongs to this class.

Tramadol Hydrochloride exerts its analgesic effect through a dual mechanism:

• Opioid mechanism: Tramadol Hydrochloride and its major active metabolite (O-desmethyltramadol, or M1) bind to and activate mu-opioid receptors in the central nervous system, reducing the perception of pain.
• Monoaminergic mechanism: Tramadol Hydrochloride inhibits the neuronal reuptake of norepinephrine and serotonin, enhancing descending inhibitory pain pathways, which contributes to analgesia independent of opioid receptor activity.

Pharmacokinetics: Tramadol Hydrochloride is well absorbed after oral administration and undergoes hepatic metabolism, primarily via CYP2D6 (to the active M1 metabolite) and CYP3A4. Metabolites are eliminated mainly via the kidneys. The elimination half-life is approximately 5–7 hours for the parent compound. Genetic variability in CYP2D6 activity (poor or ultra-rapid metabolizers) can significantly affect both efficacy and safety.

Xtrapel immediate-release capsules/tablets and oral drops may be taken with or without food. Extended-release (SR) tablets must be swallowed whole with sufficient water, once daily at approximately the same time each day, and must never be crushed, chewed, dissolved, or split. The injectable form of Xtrapel is administered by slow intravenous, intramuscular, or subcutaneous injection by a qualified healthcare professional. Do not adjust the dose or discontinue therapy abruptly without consulting a physician.

Xtrapel has several clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, is contraindicated due to risk of serotonin syndrome and increased seizure risk.
• CNS depressants (benzodiazepines, other sedatives, alcohol, other opioids, general anesthetics): Concomitant use increases the risk of profound sedation, respiratory depression, coma, and death; combined use should be avoided unless no alternative exists, with dose and duration limited.
• Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, triptans, other serotonergic agents): Increased risk of serotonin syndrome; monitor closely if co-administration is necessary.
• Strong CYP3A4 or CYP2D6 inhibitors (e.g., certain azole antifungals, macrolides) or inducers (e.g., carbamazepine, rifampicin): Can alter Xtrapel and active metabolite levels, affecting both efficacy and toxicity risk, including seizure risk.
• Drugs that lower the seizure threshold: Additive risk of seizures when used with Xtrapel.
• Warfarin and other anticoagulants: Possible potentiation of anticoagulant effect; INR monitoring is advised with concurrent use.

Side effects of Xtrapel range from common and mild to rare but serious.

Common side effects

• Nausea and vomiting
• Dizziness and headache
• Somnolence (drowsiness) and fatigue
• Constipation and dry mouth
• Sweating

Serious side effects (seek medical attention)

• Respiratory depression – see Precautions and Warnings
• Seizures – see Precautions and Warnings
• Serotonin syndrome – see Interactions and Precautions and Warnings
• Severe allergic reaction (rash, swelling, difficulty breathing)
• Dependence, abuse, and withdrawal symptoms on discontinuation – see Precautions and Warnings

Pregnancy: Xtrapel should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use. Prolonged use of Xtrapel during pregnancy can result in neonatal opioid withdrawal syndrome, which can be life-threatening if not recognized and treated, requiring management by clinicians experienced in neonatal opioid withdrawal.

Lactation: Xtrapel and its active metabolite pass into breast milk. Because of the risk of serious adverse effects, including excess sedation and respiratory depression, in a breastfed infant, breastfeeding is generally not recommended during treatment with Xtrapel; a physician should be consulted to weigh the risks and benefits and consider alternatives.

Xtrapel carries serious risks that require careful clinical judgment and patient counseling:

• Addiction, abuse, and misuse: Xtrapel exposes patients to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing and monitor regularly.
• Life-threatening respiratory depression: Risk is greatest during initiation of therapy or after dose increases, and is increased with concurrent use of CNS depressants or alcohol. Monitor closely, especially in the elderly, debilitated, or those with underlying pulmonary disease.
• Neonatal opioid withdrawal syndrome: See Pregnancy and Lactation.
• Seizure risk: Xtrapel can cause seizures, particularly at doses above the recommended range or with concurrent use of serotonergic drugs, other drugs that lower the seizure threshold, or in patients with a history of seizures, head injury, or metabolic disorders.
• Serotonin syndrome: Risk increases with concomitant serotonergic drugs – see Interactions.
• Dependence and withdrawal: Do not discontinue Xtrapel abruptly after prolonged use; taper gradually under medical supervision to avoid withdrawal symptoms.
• Impaired mental/physical abilities: Xtrapel may impair the mental or physical abilities needed to perform potentially hazardous tasks such as driving or operating machinery; avoid these activities until the effect of the drug is known.
• Adrenal insufficiency: Rare cases have been reported with prolonged opioid use; evaluate and treat if suspected.

Overdose of Xtrapel is a medical emergency. Signs and symptoms may include severe drowsiness, pinpoint pupils, cold and clammy skin, extreme respiratory depression or difficulty breathing, seizures, loss of consciousness, and cardiac arrest. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center without delay. Do not attempt to manage a suspected overdose at home; specific medical treatment (which may include airway support and reversal agents) must be administered by trained healthcare professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly (>65, especially >75 years): Use Xtrapel with caution; start at the lower end of the dosing range and titrate slowly, with close monitoring for excessive sedation and respiratory depression. Maximum immediate-release dose in patients over 75 years is 300 mg/day.

Renal impairment: In patients with creatinine clearance below 30 mL/min, extend the dosing interval for immediate-release Xtrapel to every 12 hours, with a maximum of 200 mg/day; extended-release formulations are not recommended.

Hepatic impairment: In patients with severe hepatic impairment, reduce the immediate-release dose to 50 mg every 12 hours; extended-release formulations are not recommended.

Pediatric patients: See Pediatric Uses and Contraindications.

Xtrapel should be used at the lowest effective dose for the shortest duration consistent with the treatment goals of the individual patient. For acute pain, treatment is typically limited to a few days. For chronic pain requiring extended-release Xtrapel, ongoing treatment should be periodically reassessed by the prescribing physician to confirm continued need, weighing benefits against the risks of long-term opioid therapy, including dependence.

Opioid analgesics; centrally-acting synthetic opioids with combined mu-opioid agonist and monoamine (serotonin/norepinephrine) reuptake-inhibiting activity.

Tramadol Hydrochloride acts through a dual mechanism: as a weak agonist at mu-opioid receptors in the central nervous system, and by inhibiting neuronal reuptake of norepinephrine and serotonin, thereby enhancing descending pain-inhibitory pathways. Both mechanisms contribute to its overall analgesic effect.

C

Xtrapel is contraindicated in children younger than 12 years of age due to the risk of life-threatening respiratory depression. It is also contraindicated in children and adolescents younger than 18 years of age following tonsillectomy and/or adenoidectomy. Use should be avoided in adolescents aged 12 to 18 years who have other risk factors that may increase sensitivity to opioid-induced respiratory depression (e.g., obesity, obstructive sleep apnea, severe pulmonary disease, or concomitant use of other respiratory depressants). Safety and efficacy of Xtrapel in other pediatric populations have not been established.